The Impact of Socioeconomic Status on Mortality in Patients with Hepatocellular Carcinoma: A Korean National Cohort Study-Reference-Cited by-同舟云学术

The Impact of Socioeconomic Status on Mortality in Patients with Hepatocellular Carcinoma: A Korean National Cohort Study

Published:2022-04-22 Issue:6 Volume:16 Page:976-984
ISSN:1976-2283
Container-title:Gut and Liver
language:en
Short-container-title:Gut and Liver

Author:

Yang Woo Jin¹^ORCID,Kang Danbee²^ORCID,Song Myung Gyu¹^ORCID,Seo Tae-Seok¹^ORCID,Kim Ji Hoon³^ORCID

Affiliation:

1. Department of Radiology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea

2. Department of Clinical Research Design and Evaluation, SAIHST, Sungkyunkwan University, Seoul, Korea

3. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea

Funder

Ministry of Education

National Research Foundation of Korea

Publisher

The Editorial Office of Gut and Liver

Subject

Gastroenterology,Hepatology

Link

http://pdf.medrang.co.kr/GNL/2022/016/gnl-16-6-976.pdf

Reference29 articles.

1. Improved survival of patients with hepatocellular carcinoma and disparities by age, race, and socioeconomic status by decade, 1983-2012

2. Cigarette smoking as a risk factor for the development of and mortality from hepatocellular carcinoma: An updated systematic review of 81 epidemiological studies

3. Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

4. Hepatocellular Carcinoma

5. Socio-economic status and the risk of liver cancer mortality: A prospective study in Korean men

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disparities in Overall Survival Rates for Cancers across Income Levels in the Republic of Korea;Cancers;2024-08-22

2. Analysis of Factors Predicting the Real-World Efficacy of Atezolizumab and Bevacizumab in Patients with Advanced Hepatocellular Carcinoma;Gut and Liver;2024-06-27

3. Sorafenib for 9,923 Patients with Hepatocellular Carcinoma: An Analysis from National Health Insurance Claim Data in South Korea;Gut and Liver;2023-06-19